Výsledky vyhledávání - "William J. Hyman"

Results of a Phase II Trial of Cetuximab plus Capecitabine/Irinotecan as First-Line Therapy for Patients with Advanced and/or Metastatic Colorectal Cancer

Autor: John E. Nugent, Robert L. Ruxer, Paul R. Kuefler, Kristi A. Boehm, Svetislava J. Vukelja, Donald A. Richards, Allen Lee Cohn, William J. Hyman, Maury Berger, Lina Asmar, Thomas H. Cartwright

Publikováno v: Clinical Colorectal Cancer. 7:390-397

XELIRI (capecitabine/irinotecan) is effective and well tolerated in metastatic colorectal cancer (mCRC). Cetuximab is active in mCRC alone or with chemotherapy. This study evaluated cetuximab plus XELIRI in first-line treatment of mCRC.Subjects had h

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05bb26d37446f281e2952b5f9aff8815
https://doi.org/10.3816/ccc.2008.n.052

Zobrazit plný text záznamu

Results of a Phase II Multicenter Trial of Pentostatin and Rituximab in Patients with Low-Grade B-Cell Non-Hodgkin's Lymphoma: An Effective and Minimally Toxic Regimen

Autor: Carmen Matei, William J. Hyman, David C. Faragher, Elizabeth Harden, Robert Drapkin, Nicholas J. Di Bella, Kristi A. Boehm, Mae Y. Mirabel, Lina Asmar

Publikováno v: Clinical Lymphoma. 4:169-175

This study explored the efficacy and toxicity of the combination of pentostatin and rituximab, effective single agents in low-grade non-Hodgkin's lymphoma (NHL). Sixty patients with previously treated low-grade NHL were enrolled. Except for day 1, bo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71f1ec64314f33e22b46c8d34f18e1f2
https://doi.org/10.3816/clm.2003.n.026

Zobrazit plný text záznamu

Endometrial Stromal Sarcoma Presenting as Extrauterine Metastases

Autor: Nelson G. Ordóñez, Yong W. Park, Jae Y. Ro, Timothy F. Kolda, Alberto G. Ayala, Carmen Tornos, William J. Hyman

Publikováno v: International Journal of Surgical Pathology. 5:105-110

A case of endometrial stromal sarcoma that initially presented as an umbilical mass 5 years before and as a lung lesion 8 months before the primary tumor was detected in the uterus is reported. The morphologic features and immunohistochemical profile

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5ca4937461946b2c5abf9b5b992e2879
https://doi.org/10.1177/106689699700500306

Zobrazit plný text záznamu

A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia

Autor: Kristi A. Boehm, Donald A. Richards, Nicholas J. Di Bella, Gerald J. Robbins, Lina Asmar, William J. Hyman, Mark Vellek, Roger M. Lyons, Feng Zhan, Craig W. Reynolds

Publikováno v: Investigational new drugs. 30(3)

Background Uncontrolled studies comparing pentostatin (P), cyclophosphamide (C), and rituximab (R) (PCR) to fludarabine plus C+R (FCR) suggest similar efficacy with fewer infectious complications with PCR. We compared FCR and PCR in previously-untrea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e135804b235bc61a6f2a9817156732e1
https://pubmed.ncbi.nlm.nih.gov/21922186

Zobrazit plný text záznamu

Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 24(34)

PurposeThe combination of doxorubicin and cyclophosphamide (AC) is a standard adjuvant chemotherapy regimen. Studies of docetaxel and cyclophosphamide (TC) in metastatic breast cancer (MBC) showed promise in MBC. In 1997, we initiated a randomized ad

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0427b29e7ee172a6d2d7aa5b9a86c683
https://pubmed.ncbi.nlm.nih.gov/18366954

Zobrazit plný text záznamu

Cellular immune profile of patients with advanced cancer before and after taxane treatment

Autor: B. Seamour, S. Vukelja, Donald A. Richards, John Nemunaitis, P. B. Maples, Alex W. Tong, L. Stein, J. M. Lawson, William J. Hyman, G. Ordonez

Publikováno v: American journal of clinical oncology. 23(5)

The purpose of this study is to determine immune recovery and function after treatment with docetaxel or paclitaxel. Peripheral blood mononuclear cells were harvested before chemotherapy and at weekly times afterwards for cycle 1. Leukocyte subsets I

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::061171cc0337118322b9a19ff241b02d
https://pubmed.ncbi.nlm.nih.gov/11039505

Zobrazit plný text záznamu

Randomized, double-blind, placebo-controlled trial to evaluate the hematopoietic growth factor PIXY321 after moderate-dose fluorouracil, doxorubicin, and cyclophosphamide in stage II and III breast cancer

Autor: Tammy Roque, Edward Agura, Mary Lange, Douglas Orr, Pankaj Khandelwal, Robert G. Mennel, Kristi J. McIntyre, Michael W. Schuster, Leslie Garrison, Robert Kirby, Lewis Duncan, Stephen E. Jones, Nikolay V. Dimitrov, William J. Hyman, David H. Regan

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 17(10)

PURPOSE: To measure the effect of PIXY321 (granulocyte-macrophage colony-stimulating factor/interleukin-3 S. cerevisiae fusion protein) on the incidence, duration, and complications of neutropenia and thrombocytopenia after moderate-dose fluorouracil

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9efabab332911c3d809451e762b7b9a1
https://pubmed.ncbi.nlm.nih.gov/10506596

Zobrazit plný text záznamu

Phase I study of pemetrexed (P) and pegylated liposomal doxorubicin (PLD) in patients with refractory breast, ovarian, primary peritoneal, or fallopian tube cancer

Autor: Donald A. Richards, Oluwatoyin O. Shonukan, William J. Hyman, J. Nieves, Hillary H. Wu, S. Hu, Yunfei Wang, David M. Loesch, D. Tai, Svetislava J. Vukelja

Publikováno v: Journal of Clinical Oncology. 27:e13515-e13515

e13515 Background: P and PLD are clinically active as single agents and synergistic in preclinical models. This phase I, open-label trial determined the maximum tolerated dose (MTD) and safety profile of P followed by PLD in patients (pts) with breas

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3b846e48a8efc8ff8ea2c75b079ecd0a
https://doi.org/10.1200/jco.2009.27.15_suppl.e13515

Zobrazit plný text záznamu

Randomized phase II study of perifosine in combination with capecitabine versus capecitabine alone in patients with second- or third-line metastatic colon cancer

Autor: C. Bedell, L. T. Campos, Svetislava J. Vukelja, Donald A. Richards, J. P. Letzer, William J. Hyman, Peter Sportelli, L. Gardner, John Nemunaitis, Christopher Hagenstad

Publikováno v: Journal of Clinical Oncology. 27:4081-4081

4081 Background: Perifosine (Peri), a synthetic alkylphospholipid, inhibits or modifies a number of different signal transduction pathways (AKT, MAPK and JNK). Peri as a single agent or in combination with other cytotoxic agents, has shown clinical b

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e6bb55f0a4708f86ea41e01d9f54daeb
https://doi.org/10.1200/jco.2009.27.15_suppl.4081

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání